Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E.

Lancaster E, Li J, Hanania T, Liem R, Scheideler MA, Scherer SS.

Exp Neurol. 2018 Oct;308:13-25. doi: 10.1016/j.expneurol.2018.06.010. Epub 2018 Jun 22.

PMID:
29940160
2.

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

Zhao HT, Damle S, Ikeda-Lee K, Kuntz S, Li J, Mohan A, Kim A, Hung G, Scheideler MA, Scherer SS, Svaren J, Swayze EE, Kordasiewicz HB.

J Clin Invest. 2018 Jan 2;128(1):359-368. doi: 10.1172/JCI96499. Epub 2017 Dec 4.

3.

Schwann cell overexpression of the GPR7 receptor in inflammatory and painful neuropathies.

Zaratin PF, Quattrini A, Previtali SC, Comi G, Hervieu G, Scheideler MA.

Mol Cell Neurosci. 2005 Jan;28(1):55-63.

PMID:
15607941
4.

Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system.

Larminie C, Murdock P, Walhin JP, Duckworth M, Blumer KJ, Scheideler MA, Garnier M.

Brain Res Mol Brain Res. 2004 Mar 17;122(1):24-34.

PMID:
14992813
5.

Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).

Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Scheideler MA.

J Pharmacol Exp Ther. 2004 Feb;308(2):454-61. Epub 2003 Oct 30.

PMID:
14593080
6.

4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity.

Piaz VD, Vergelli C, Giovannoni MP, Scheideler MA, Petrone G, Zaratin P.

Farmaco. 2003 Nov;58(11):1063-71.

PMID:
14572856
7.
8.

PTH2 receptor-mediated inhibitory effect of parathyroid hormone and TIP39 on cell proliferation.

Misiano P, Scott BB, Scheideler MA, Garnier M.

Eur J Pharmacol. 2003 May 16;468(3):159-66.

PMID:
12754053
9.

Up-regulation of regulator of G protein signaling 4 expression in a model of neuropathic pain and insensitivity to morphine.

Garnier M, Zaratin PF, Ficalora G, Valente M, Fontanella L, Rhee MH, Blumer KJ, Scheideler MA.

J Pharmacol Exp Ther. 2003 Mar;304(3):1299-306. Erratum in: J Pharmacol Exp Ther. 2003 May;305(2):797.

PMID:
12604710
10.

Recent advances in the development of dopamine D(3) receptor agonists and antagonists.

Crider AM, Scheideler MA.

Mini Rev Med Chem. 2001 May;1(1):89-99. Review.

PMID:
12369994
11.

The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death.

Moroni F, Attucci S, Cozzi A, Meli E, Picca R, Scheideler MA, Pellicciari R, Noe C, Sarichelou I, Pellegrini-Giampietro DE.

Neuropharmacology. 2002 May;42(6):741-51.

PMID:
12015200
12.

Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.

Taylor JW, Jin QK, Sbacchi M, Wang L, Belfiore P, Garnier M, Kazantzis A, Kapurniotu A, Zaratin PF, Scheideler MA.

J Med Chem. 2002 Feb 28;45(5):1108-21.

PMID:
11855991
13.
14.

Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.

Blaney FE, Raveglia LF, Artico M, Cavagnera S, Dartois C, Farina C, Grugni M, Gagliardi S, Luttmann MA, Martinelli M, Nadler GM, Parini C, Petrillo P, Sarau HM, Scheideler MA, Hay DW, Giardina GA.

J Med Chem. 2001 May 24;44(11):1675-89.

PMID:
11356103
15.

SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.

Videbaek C, Toska K, Scheideler MA, Paulson OB, Moos Knudsen G.

Synapse. 2000 Dec 1;38(3):338-42.

PMID:
11020237
16.

Synthesis and antinociceptive activity of pyrrolidinylnaphthalenes.

Collina S, Azzolina O, Vercesi D, Sbacchi M, Scheideler MA, Barbieri A, Lanza E, Ghislandi V.

Bioorg Med Chem. 2000 Aug;8(8):1925-30.

PMID:
11003137
17.

Dopamine D1B receptor chimeras reveal modulation of partial agonist activity by carboxyl-terminal tail sequences.

Sugamori KS, Scheideler MA, Vernier P, Niznik HB.

J Neurochem. 1998 Dec;71(6):2593-9.

18.

Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012.

Sugamori KS, Hamadanizadeh SA, Scheideler MA, Hohlweg R, Vernier P, Niznik HB.

J Neurochem. 1998 Oct;71(4):1685-93.

19.

Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI.

Fink-Jensen A, Nielsen EB, Hansen L, Scheideler MA.

Eur J Pharmacol. 1998 Jan 26;342(2-3):153-61.

PMID:
9548380
20.

The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain.

Scheideler MA, Martin J, Hohlweg R, Rasmussen JS, Naerum L, Ludvigsen TS, Larsen PJ, Korsgaard N, Crider AM, Ghosh D, Cruse SF, Fink-Jensen A.

Eur J Pharmacol. 1997 Nov 27;339(2-3):261-70.

PMID:
9473144
21.

Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.

Pak Y, Kouvelas A, Scheideler MA, Rasmussen J, O'Dowd BF, George SR.

Mol Pharmacol. 1996 Nov;50(5):1214-22.

PMID:
8913353
22.

Behavioural and anticonvulsant effects of Ca2+ channel toxins in DBA/2 mice.

Jackson HC, Scheideler MA.

Psychopharmacology (Berl). 1996 Jul;126(1):85-90.

PMID:
8853221
23.

The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 and GPR8, expressed in discrete areas of the brain.

O'Dowd BF, Scheideler MA, Nguyen T, Cheng R, Rasmussen JS, Marchese A, Zastawny R, Heng HH, Tsui LC, Shi X, et al.

Genomics. 1995 Jul 1;28(1):84-91.

PMID:
7590751
24.
25.

Glycerophosphate acyltransferase from Escherichia coli.

Scheideler MA, Bell RM.

Methods Enzymol. 1992;209:55-63. No abstract available.

PMID:
1495435
26.

High efficiency reconstitution of a phencyclidine/MK-801 receptor binding site solubilized from rat forebrain membranes.

Haring R, Pellegrini-Giampietro DE, Zukin SR, Zukin RS, Scheideler MA.

Mol Pharmacol. 1991 Nov;40(5):666-73.

PMID:
1658603
28.

Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation.

Haring R, Stanton PK, Scheideler MA, Moskal JR.

J Neurochem. 1991 Jul;57(1):323-32.

PMID:
1828831
29.

Reconstitution of solubilized delta-opiate receptor binding sites in lipid vesicles.

Scheideler MA, Zukin RS.

J Biol Chem. 1990 Sep 5;265(25):15176-82.

30.
31.
32.
33.
34.

Supplemental Content

Loading ...
Support Center